Astellas become first Japanese pharmaceutical branch with KRW 200 billion annual sales

Astellas Pharma Korea(CEO Hae-do Jung) has enter the sales wall of KRW 200 billion for the first time as a Japanese multinational pharmaceutical company branched in the Korean market.

According to the electronic official notice on the 6^th, Astellas, a corporate body which balance accounts on March, rapidly grew 17.5% up as recording KRW 234.7 billion sales last year(April 2015-March 2016) com...